Spruce Biosciences, Inc.
A clinical-stage biopharmaceutical company developing drug therapies for rare endocrine (hormone) disorders. Its lead experimental medicine, tildacerfont, is being studied for people living with congenital adrenal hyperplasia, a rare genetic condition that disrupts the body's hormone production. Founded in 2013 and based in South San Francisco, the company went public on the US stock market in 2021.
Bought 250.0K
Bought 250.0K
Bought 2.46M · Sold 4.65M
Bought 250.0K
Bought 250.0K
Bought 200.0K
Bought 250.0K
Bought 880.4K
Granted 231.1K
Granted 723.5K
Granted 524.7K
Bought 256 · Sold 257
Bought 256 · Sold 257
Granted 1.3K
Granted 14.4K · Sold 14.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| RiverVest Venture Fund III (Ohio), L.P. +2 co-filers10% owner · 3 transactions | — | 5.12Mas of Oct 2020 | — | 250.0K | — |
| Chaya Moghrabi DinaDirector · 2 transactions | — | 4.07Mas of Oct 2020 | — | 250.0K | — |
| Novo Holdings A/S10% owner · 9 transactions | — | 2.55Mas of Mar 2024 | — | 2.46M | 4.65M |
| Omega Fund VI GP Manager, Ltd. +2 co-filers10% owner, Former 10% Owner · 2 transactions | — | 2.16Mas of Oct 2020 | — | 250.0K | — |
| Hansson JonasDirector · 2 transactions | — | 2.03Mas of Oct 2020 | — | 250.0K | — |
| Muralidhar BaliDirector · 2 transactions | — | 1.79Mas of Oct 2020 | — | 200.0K | — |
| HealthCap VIII, L.P.Former 10% Owner · 2 transactions | — | 1.78Mas of Oct 2020 | — | 250.0K | — |
| O'Donnell NiallDirector · 3 transactions | — | 1.33Mas of Feb 2023 | — | 880.4K | — |
| Charlton Ralph William IIICHIEF MEDICAL OFFICER · 11 transactions | — | 150.4Kas of Dec 2024 | 231.1K | — | — |
| Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER, Director · 21 transactions | — | 19.0K | 723.5K | — | — |
| Gharib Samir M.PRESIDENT AND CFO · 31 transactions | — | 8.3K | 524.7K | — | — |
| Parkman Healthcare Partners LLC10% owner · 3 transactions | — | 2.4K | — | 256 | 257 |
| King RichardChief Executive Officer, Director · 1 transaction | — | 2.2Kas of Jun 2021 | — | — | — |
| Martinez Gregory +1 co-filer10% owner · 3 transactions | — | 2.1K | — | 256 | 257 |
| Ways Douglas KirkInterim Chief Medical Officer, Director · 1 transaction | — | 1.3K | 1.3K | — | — |
| Simpson Camilla VDirector · 4 transactions | — | 334as of May 2021 | 14.4K | — | 14.4K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +126.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.